• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    KKR & Co. Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    2/5/26 6:02:36 AM ET
    $KKR
    Investment Managers
    Finance
    Get the next $KKR alert in real time by email
    false000140491200014049122026-02-042026-02-040001404912kkr:Four625SubordinatedNotesDue2061OfKKRGroupFinanceCoIXLLCMember2026-02-042026-02-040001404912us-gaap:CommonStockMember2026-02-042026-02-040001404912kkr:Six25SeriesDMandatoryConvertiblePreferredStockMember2026-02-042026-02-040001404912kkr:Six875SubordinatedNotesDue2065Member2026-02-042026-02-04

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549



    FORM 8-K
     
    CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): February 4, 2026
     
    KKR & Co. Inc.
    (Exact name of registrant as specified in its charter)

    Delaware
    001-34820
    88-1203639
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)
     
    30 Hudson Yards
    New York, NY 10001
    Telephone: (212) 750-8300
     
    (Address, zip code, and telephone number, including area code, of registrant's principal executive office.)
     
    NOT APPLICABLE
    (Former name or former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading symbol(s) Name of each exchange on which registered
    Common Stock
    KKR
    New York Stock Exchange
    4.625% Subordinated Notes due 2061 of KKR Group Finance Co. IX LLC
    KKRS
    New York Stock Exchange
    6.25% Series D Mandatory Convertible Preferred Stock
    KKR PR D
    New York Stock Exchange
    6.875% Subordinated Notes due 2065
    KKRT
    New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    ☐
    Emerging growth company
     
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



    Item 3.02.
    Unregistered Sales of Equity Securities
     
    On February 4, 2026, KKR Summit Holdings L.P. (“Buyer”), an indirect subsidiary of KKR & Co. Inc. (the “Company” and, together with its subsidiaries, “KKR”), entered into a definitive agreement to acquire 100% of Arctos Partners, LP (“Arctos”), an investment firm that provides strategic growth capital and liquidity solutions to sports franchises through its Arctos Sports family of funds and to private investment fund sponsors through its Arctos Keystone family of funds.  The closing of the acquisition (the “Closing”) is subject to the satisfaction of regulatory and specified sports approvals as well as other customary conditions.

    Subject to Closing, KKR has agreed to pay $1.4 billion in initial consideration for the seller’s equity interests in Arctos, consisting of cash and equity securities of KKR.  The equity component of this initial consideration includes (i) $900 million of equity securities paid to existing Arctos shareholders including Arctos management, with management’s equity securities subject to vesting through 2030, and (ii) $200 million of additional equity securities to be allocated by 2028 and subject to vesting through 2033. The initial consideration for the acquisition also includes $300 million of cash, subject to contractual purchase price adjustments and other adjustments. In addition, equity of up to $550 million tied to both KKR share price and business-specific performance targets and subject to vesting through 2031 may be earned. The number of shares or units issuable in connection with the initial equity consideration of $1.1 billion will be calculated using $130.62 per share of common stock of the Company (“KKR Common Stock”). The share price used to determine the equity units subject to the business-specific performance targets will be calculated using the daily volume weighted average price per share of the KKR Common Stock for the 20 consecutive trading day period ending on (and including) December 29, 2028 (the “Year-End 2028 Price”). The share price used to determine the units subject to the KKR share price targets will be calculated using the highest applicable KKR share price target, which will be set at Closing.

    Certain of the equity securities in the initial consideration and the potential additional equity will be unregistered securities issuable pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. The unregistered securities include $920 million of the $1.1 billion initial equity consideration comprised of the following: (i) 1.504 million shares of KKR Common Stock and (ii) 5.540 million of restricted holdings units that once vested are exchangeable for shares of KKR Common Stock on a one-for-one basis (“KKR Restricted Units”). In addition, $415 million of the $550 million potential additional securities that are subject to KKR share price and business-specific performance targets will be unregistered KKR Restricted Units. The remaining equity components of the initial consideration and potential additional equity are expected to be registered and issued under the Company’s equity incentive plan.

    Item 7.01
    Regulation FD Disclosure.

    On February 5, 2026, the Company and Arctos issued a joint press release announcing the entry into definitive agreements with respect to the
    acquisition of Arctos. The press release is furnished as Exhibit 99.1 to this report.  The Company also posted a presentation on its website for KKR common stockholders and analysts entitled “KKR & Co. Inc. Acquisition of Arctos”. The presentation is accessible at the Investor Center for KKR & Co. Inc. at https://ir.kkr.com/events-presentations/. From time to time, KKR uses its website as a channel of distribution of financial and other important information about the company. Information on the website is not incorporated by reference herein and is not a part of this Form 8-K.

    As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

    Item 9.01
    Financial Statements and Exhibits.
     
    (d)
    Exhibits

    Exhibit No.
     
    Description
    Exhibit 99.1
     
    Joint Press Release of KKR & Co. Inc. and Arctos Partners, LP, dated February 5, 2026.
    Exhibit 104
     
    Cover Page Interactive Data File, formatted in Inline XBRL


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    KKR & CO. INC.
         



    Date: February 5, 2026
    By:


    Name: Christopher Lee

    Title: Secretary
     


    Get the next $KKR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KKR

    DatePrice TargetRatingAnalyst
    2/24/2026$137.00Outperform
    RBC Capital Mkts
    1/28/2026$144.00Hold → Buy
    HSBC Securities
    1/14/2026$131.00Buy → Hold
    TD Cowen
    12/11/2025$176.00Buy
    UBS
    7/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    7/9/2025$142.00Buy → Hold
    HSBC Securities
    6/30/2025$150.00Overweight
    Piper Sandler
    5/14/2025$150.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $KKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barakett Timothy R bought $4,723,500 worth of shares (50,000 units at $94.47) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/5/26 7:30:13 PM ET
    $KKR
    Investment Managers
    Finance

    Director Dillon Mary N bought $2,021,586 worth of shares (22,225 units at $90.96) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:01 PM ET
    $KKR
    Investment Managers
    Finance

    Co-Chief Executive Officer Bae Joseph Y bought $4,428,000 worth of shares (50,000 units at $88.56) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:04 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Kkr Group Partnership L.P.

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    3/10/26 5:15:24 PM ET
    $KKR
    Investment Managers
    Finance

    Director Barakett Timothy R bought $4,723,500 worth of shares (50,000 units at $94.47) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/5/26 7:30:13 PM ET
    $KKR
    Investment Managers
    Finance

    Large owner Kkr Group Partnership L.P. sold $807,546,115 worth of shares (19,715,000 units at $40.96), disposed of 402,773 shares and gifted 81,213 shares (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    3/4/26 7:46:52 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on KKR with a new price target

    RBC Capital Mkts initiated coverage of KKR with a rating of Outperform and set a new price target of $137.00

    2/24/26 7:55:00 AM ET
    $KKR
    Investment Managers
    Finance

    KKR upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded KKR from Hold to Buy and set a new price target of $144.00

    1/28/26 7:11:28 AM ET
    $KKR
    Investment Managers
    Finance

    KKR downgraded by TD Cowen with a new price target

    TD Cowen downgraded KKR from Buy to Hold and set a new price target of $131.00

    1/14/26 8:26:34 AM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    SEC Filings

    View All

    SEC Form DEFA14A filed by KKR & Co. Inc.

    DEFA14A - KKR & Co. Inc. (0001404912) (Filer)

    3/2/26 8:32:24 AM ET
    $KKR
    Investment Managers
    Finance

    SEC Form DEFA14A filed by KKR & Co. Inc.

    DEFA14A - KKR & Co. Inc. (0001404912) (Filer)

    2/27/26 5:01:59 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form DEFA14A filed by KKR & Co. Inc.

    DEFA14A - KKR & Co. Inc. (0001404912) (Filer)

    2/27/26 5:00:39 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KKR Income Opportunities Fund Declares Monthly Distributions of $0.1215 Per Share

    KKR Income Opportunities Fund (the "Fund") (NYSE:KIO) today announced its monthly distributions of $0.1215 per common share, payable on the dates below. Based on the Fund's current share price of $11.04 per share (as of market close on March 9, 2026), the distributions represent an annualized distribution rate of 13.21%, (calculated by annualizing the distribution amount and dividing it by the current price). The monthly distribution schedule is as follows for the months of April, May, and June: Ex-Date: April 10, 2026 Record Date: April 10, 2026 Payable Date: April 30, 2026     Ex-Date: May 8, 2026 Record Date:

    3/10/26 5:23:00 PM ET
    $KIO
    $KKR
    Investment Managers
    Finance

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    KKR to Present at the 2026 RBC Capital Markets Financial Institutions Conference

    KKR & Co. Inc. (NYSE:KKR) announced today that Robert H. Lewin, Chief Financial Officer, will present at the 2026 RBC Capital Markets Financial Institutions Conference on Wednesday, March 11, 2026 at 9:20AM ET. A live webcast of the presentation will be available on the Investor Center section of KKR's website at https://ir.kkr.com/events-presentations/. For those unable to listen to the live webcast, a replay will be available on the website shortly after the event. Any questions regarding the webcast may be addressed to KKR's Investor Relations team at [email protected]. ABOUT KKR KKR is a leading global investment firm that offers alternative asset management as well as

    2/26/26 4:15:00 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Leadership Updates

    Live Leadership Updates

    View All

    KKR-led Consortium Drives Further Investment in Sylvan

    Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the "Company"), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/ Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential

    1/20/26 8:02:00 PM ET
    $KKR
    Investment Managers
    Finance

    Peak Re Welcomes KKR and Quadrantis Capital as Minority Investors

    Peak Reinsurance Company Limited ("Peak Re" or the "Company") and KKR, a leading global investment firm, today announced that funds managed by KKR and Quadrantis Capital have entered into definitive agreements to acquire minority stakes in Peak Re via Peak Reinsurance Holdings Limited. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020924186/en/ Upon completion, KKR and Quadrantis Capital are expected to hold approximately 11.27% and approximately 1.80% of Peak Re's issued share capital, respectively, with the remaining approximately 86.71% continuing to be held by the majority shareholder, Fosun International Limited. Pruden

    10/20/25 9:05:00 PM ET
    $KKR
    Investment Managers
    Finance

    KKR Appoints Craig Arnold to Board

    KKR & Co. Inc. (NYSE:KKR) today announced that Craig Arnold has been appointed to the Board of Directors effective September 23, 2025. His appointment will bring the number of independent directors to eleven out of a total of fifteen Board seats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250924641078/en/Craig Arnold Mr. Arnold is the former Chairman and Chief Executive Officer of Eaton Corporation, a global intelligent power management company. KKR's other Board members are: Henry Kravis (Co-Founder and Co-Executive Chairman of KKR), George Roberts (Co-Founder and Co-Executive Chairman of KKR), Joseph Bae (Co-Executive Of

    9/24/25 4:30:00 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Financials

    Live finance-specific insights

    View All

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    FS KKR Capital Corp. Announces Fourth Quarter and Full Year 2025 Results; Declares First Quarter 2026 Distribution of $0.48 per Share

    PHILADELPHIA and NEW YORK, Feb. 25, 2026 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK), or the Company, today announced its financial and operating results for the quarter and year ended December 31, 2025, and that its board of directors has declared a first quarter 2026 distribution of $0.48 per share. Financial and Operating Highlights for the Quarter Ended December 31, 2025(1)Net investment income of $0.48 per share, compared to $0.57 per share for the quarter ended September 30, 2025Adjusted net investment income(2) of $0.52 per share, compared to $0.57 per share for the q

    2/25/26 4:15:00 PM ET
    $FSK
    $KKR
    Investment Managers
    Finance

    Keurig Dr Pepper Announces Updated Financing Plan for JDE Peet's Acquisition

    Company strengthens balance sheet by further reducing projected leverage and attracts additional high-quality investorsBURLINGTON, Mass. and FRISCO, Texas, Feb. 23, 2026 /PRNewswire/ -- Keurig Dr Pepper Inc. (NASDAQ:KDP, ", the Company", )) today announced updated financing plans and transaction timelines for the acquisition of JDE Peet's and subsequent planned separation into two independent companies ("Beverage Co." and "Global Coffee Co." pending the announcement of official corporate names).Key developments include:A targeted close of the JDE Peet's acquisition in early April 2026, with expected combined net leverage of approximately 4.5x1An agreement to upsize the previously announced B

    2/23/26 4:30:00 PM ET
    $APO
    $KDP
    $KKR
    Investment Managers
    Finance
    Beverages (Production/Distribution)
    Consumer Staples

    $KKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/12/24 3:50:17 PM ET
    $KKR
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/4/24 11:48:27 AM ET
    $KKR
    Investment Managers
    Finance

    SEC Form SC 13G/A filed by KKR & Co. Inc. (Amendment)

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    2/13/24 6:32:37 PM ET
    $KKR
    Investment Managers
    Finance